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Abstract: Nemertines are a phylum of carnivorous marine worms that possess a variety of 
alkaloidal, peptidic or proteinaceous toxins that serve as chemical defenses against potential 
predators. The hoplonemertines additionally envenomate their prey with a mixture of 
proboscis alkaloids delivered with the help of a calcareous stylet that punctures the skin of 
the victim. Anabaseine, the first of these alkaloids to be identified, stimulates a wide variety 
of animal nicotinic acetylcholine receptors (AChRs), especially the neuromuscular [e.g., 
α12β1γδ (embryogenic) or α12β1γε (adult)] and α7 AChRs that are inhibited by the snake 
peptide α-bungarotoxin. A synthetic derivative, 3-(2,4-Dimethoxybenzylidene)-Anabaseine 
(DMXBA; also called GTS-21), improves memory in experimental animals and humans and 
is currently in clinical trials to determine whether it can ameliorate cognitive problems 
associated with schizophrenia. Here we summarize present knowledge concerning the 
chemistry and mechanisms of action of these two substances (anabaseine and DMXBA) on 
AChRs, especially those found in the mammalian brain. 
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long-term potentiation; NMDA; CNS, central nervous system; N-methyl-D-aspartate; 5-HT; 
5-hydroxytryptamine or serotonin; AD, Alzheimer’s disease; Aβ, β-amyloid; PTHP, 2-
(3,4,5,6-tetrahydropyrimidinyl)-3-pyridine; PCP, phencyclidine; Ki, inhibition constant. 
 
Introduction 
The Belgian pharmacologist Bacq discovered the existence of toxins in nemertines during the mid-
1930s while searching for invertebrate neurotransmitters. An aqueous homogenate of a small intertidal 
hoplonemertine species (Amphiporus lactifloreus), like acetylcholine (ACh), contracted isolated frog 
skeletal muscle and stimulated the cat cervical autonomic ganglion. Unlike ACh the cholinergic 
activity of the homogenate was stable in highly alkaline solution and was soluble in organic solvents 
under basic conditions. On the basis of this somewhat limited profile Bacq [15,16] inferred that 
"amphiporine" was an alkaloid similar to nicotine. King [52] showed that amphiporine acted as an 
organic base and attempted its further purification by crystallization with standard alkaloidal 
precipitants, however a crystalline salt was not obtained. 
Nemertines are a phylum of carnivorous, mainly marine worms [32]. While over a 1,000 species 
have been described, the actual number of species in this inconspicuous phylum is likely to be several 
times this figure. Being soft-bodied and relatively vulnerable to predators, they contain integumentary 
toxins which serve as chemical defenses against predators [39,42,43,45,50]. The phylum is roughly 
divided into two large groups, the Enoplans (hoplonemertines) bearing a mineralized proboscis stylet 
and the Anoplans (paleo- and heteronemertines) lacking a stylet. The relatively small size of most 
nemertines makes them more difficult to collect than many aquatic animals. Another problem is 
species identification, as the external morphologies of some species may be so similar that the 
preparation of fixed and stained tissue sections for histological examination may be necessary for 
unequivocal identification. Nonetheless, the phylum undoubtedly represents an unusually rich source 
of alkaloid, peptide and protein toxins, most of them still awaiting investigation. 
Approximately thirty years elapsed after Bacq’s discovery before another study of nemertine toxins 
was reported [46]. Extracts of most species were found to be toxic to crustaceans, but only those of 
hoplonemertines displayed nicotinic agonist properties and contained pyridyl alkaloids [39,40]. The 
heteronemertines were shown to contain basic peptide and protein neurotoxins and cytotoxins [41]. 




This first nemertine alkaloid to be isolated and identified, anabaseine, occurs in relatively large 
concentrations in the intertidal Pacific nemertine Paranemertes peregrina [46]. The "peregrine" 
(wandering) designation refers to the relatively unique foraging behavior of this moderately large (>15 
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cm) species: it glides along the exposed surface of mud flats at low tide searching for annelid worms in 
full view of potential predators such as seagulls, raccoons and other large predators. Several thousand 
worms were collected and an alkaloid fraction was obtained from the ethanolic extract, much as 
described by King [52]. Because more than a gram of alkaloid was isolated, it was possible to obtain a 
homogeneous picrate salt, even though in relatively small yield [46]. After conversion back to the free 
base, nuclear magnetic resonance and mass spectrometric analyses indicated that the alkaloid was 
anabaseine, a previously synthesized compound that had not been reported as a natural product. This 
was corroborated by comparison of the chemical and toxicological properties of natural and synthetic 




Figure 1. Anatomy of the proboscis apparatus in a hoplonemertine worm. (a) The apparatus is 
in the resting (retracted) position. (b) The apparatus is in the protruded position, the anterior 
part has been everted so that the stylet can puncture the surface of the prey and thus facilitate 
entry of the venom. Key: a.p., anterior proboscis epithelium; c.s., central stylet; p.p., posterior 
proboscis epithelium; r., rhynchocoel; r.e., rhynchocoel endothelium; r.m., proboscis retractor 
muscle (modified from Gibson [32]). 
 
Anabaseine is chemically similar to the tobacco alkaloid, anabasine, but possesses an imine double 
bond in the otherwise saturated piperidine ring (Fig. 2). Imine-enamine tautomerism constrains the β-
carbon to lie within the same plane as the α-carbon and the imine nitrogen. This tautomeric system is 
conjugated with the π electrons of the pyridyl ring. This electronic conjugation strongly favors the two 
rings of anabaseine being approximately co-planar with respect to each other. This contrasts with 
nicotine and anabasine, whose respective pyrrolidine and piperidine rings are oriented approximately 
at right angles in their preferred conformations. Anabaseine was first prepared as an intermediate in 
the synthesis of anabasine by two Austrian tobacco chemists [77]. A mixed aldol-like condensation 
reaction between nicotinic acid ethyl ester and N-benzoyl piperidone yielded the expected diketone, 
which rearranged in the presence of concentrated hydrochloride acid at high temperature to anabaseine 
hydrochloride. Conversion of the salt to the free base, extraction of the free base with organic solvent 
and purification by distillation, the method reported by Spath and Mamoli [77] or column 
chromatography generally provided anabaseine in relatively low yields [40,46]. Subsequent 
modifications have provided a more efficient synthesis and isolation in much higher yields [18]. 
Synthetic anabaseine dihydrochloride (M.W. 251) obtained in this manner exists as the ammonium-
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ketone form and contains one molecule of water. While stable as the dried salt, aqueous solutions of 
anabaseine hydrochloride should be refrigerated when not in use and replaced after several weeks. The 
cationic forms of anabaseine are quite soluble in protic solvents such as water, methanol and ethanol, 
but the more lipophilic free base is best dissolved in non-aqueous solvents such as alcohols, acetone, 
or ethyl acetate. 
Although anabaseine appears to be chemically simple, it actually occurs in several different forms 
under physiological conditions [95,96]. At neutral pH there are three forms in roughly equal 
concentrations: the unprotonated cyclic imine, the monocationic cyclic iminium and the 
monocationic ammonium-ketone (Fig. 3). This multiplicity complicated our initial attempts to 
determine which forms interact with AChRs based upon the pH dependence of anabaseine potency, 
so stable analogs of each form were prepared so that the pharmacological properties of the different 
forms could be inferred. 2,3'-Bipyridyl [47], which can be prepared by oxidation of anabaseine or 
anabasine, is predicted to possess a chemical conformation similar to the cyclic imine, so it was 
selected as an analog of the unprotonated form, while 2-(3,4,5,6-tetrahydropyrimidinyl)-3-pyridine 
(PTHP) was selected as a stable permanently ionized analog of the cyclic iminium form. Two stable 
analogs of the open-chain ammonium-ketone form were prepared by di- or tri-methylation of the 
ammonium group. Amongst the various stable analogs, only PTHP potently stimulated skeletal 
muscle and brain nicotinic acetylcholine receptor (AChR)-expressing cells (Kem et al., in 
preparation). Thus, we conclude that only the cyclic iminium form of anabaseine is active on these 





Figure 2. Structure of (S)-nicotine, anabaseine and its 2,4-dimethoxybenzylidene derivative, 
DMXBA. While nicotine and anabaseine stimulate a wide variety of vertebrate AChRs, 
DMXBA selectively stimulates α7-type AChRs.  
 
AChRs are a family of receptors that belong to the Cys-loop ligand-gated ion channel superfamily 
that includes types A and C γ-amminobutyric acid, glycine, and type 3 serotonin (5-hydroxytryptamine; 
5-HT) receptors (reviewed in [3,4]). In the peripheral nervous system, AChRs can be subdivided into 
muscle-type, that have the stoichiometry α12β1δγ (embryonic or Torpedo) or α12β1δε (adult), and 
ganglionic AChRs (e.g., α3β4). In the central nervous system (CNS), AChRs are of two main 
subclasses: receptors that bind the competitive antagonist α-bungarotoxin (α-BTx) with high affinity 
but the agonist nicotine with low affinity (e.g., α7-containing receptors), and AChRs that bind nicotine 
with high affinity but α-BTx with low affinity (e.g., α4β2-containing receptors).  
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The physiological and pharmacological effects of anabaseine on a variety of vertebrate AChRs were 
previously reported [49]. Like nicotine, anabaseine stimulates all AChRs to some degree and thus must 
be classified as a non-selective nicotinic agonist. However, it preferentially stimulates the same 
AChRs (e.g., skeletal muscle and brain α7 subtypes) that display high affinities for the snake toxin α-
BTx. In contrast, nicotine preferentially and almost fully stimulates α4β2 (brain) and α3β4 
(predominantly autonomic) receptors. Anabaseine is a full agonist at the α7 receptor but only a very 
weak (low efficacy) agonist at the α4β2 subtype. The maximal effect of nicotine on the latter receptor 
is much greater than its maximal effect on the α7 receptor. Since nicotine also binds to α4β2 receptors 
at much lower (about 100-fold) concentrations than to the α7 receptor, its in vivo effects at “smoking” 
concentrations are most likely mediated through β2 subunit-containing receptors. Anabaseine 
stimulates PC12 cell and guinea pig ileum AChRs thought to contain α3β4 (and probably other) 
autonomic receptors. A more recent study of anabaseine action on rat AChRs expressed in Xenopus 




Figure 3. Equilibrium between the four major forms of anabaseine in aqueous solution as a 
function of pD [95]. Note that pD = pH + 0.4. 
 
The whole animal (mouse) toxicity of anabaseine is very similar to that of nicotine and is 
significantly higher than for anabasine [47,54]. Nicotine toxicity is likely due to convulsions mediated 
by stimulation of CNS α4β2 AChRs. In contrast, anabaseine has very weak partial agonist activity at 
this receptor and probably exerts its toxicity by causing peripheral neuromuscular block and 
respiratory arrest. Because of its high toxicity and relative lack of receptor selectivity, few in vivo 
studies have been carried out with anabaseine. The significantly higher potency of nicotine relative to 
anabaseine in causing prostration is consistent with the notion that α4β2 receptors primarily mediate 
this characteristic behavior [49]. 
Anabaseine also affects a variety of invertebrate AChRs. Marine annelids which are the usual prey 
for Paranemertes are paralyzed, as are crustaceans and insects. Nicotinic cholinergic receptors 
primarily reside on central neurons in arthropods, but are also found in their cardiac pacemaker 
ganglion. 2,3'-Bipyridyl, a largely unionized analog of anabaseine, is even more active than anabaseine 
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in paralyzing crustaceans [47]. While it does not cause paralysis, nemertelline (a tetrapyridyl found in 
Amphiporus angulatus), like anabaseine and 2,3'-bipyridyl, stimulates an unusual receptor in the 
stomatogastric muscle of the crayfish which is apparently a chloride channel [50]. At present this is the 
only known action of this alkaloid, which is the most abundant pyridine in this species of Amphiporus. 
A variety of pyridine compounds including anabaseine and 2,3'-bipyridyl stimulate chemoreceptor 
present in sensory neurons present at the surfaces of crayfish and lobster walking legs that influence 
feeding behavior [35]. Anabaseine and 2,3'-bipyridyl were found to be two of the most active 
compounds in stimulating similar pyridine receptors on spiny lobster sensory nerves [50]. The 
nemertine alkaloids, by acting upon these chemoreceptors, may act as repellants against certain 
predators. Some of these compounds are also able to inhibit the settlement of barnacle larvae to marine 
surfaces and thus might be useful “antifouling” additives to marine paints. 
DMXB-Anabaseine (DMXBA), A Synthetic Anabaseine Derivative 
While anabaseine is a broad spectrum nicotinic agonist, a large variety (>200) of substituted 
anabaseines that have been synthesized over the past two decades displayed selective agonistic effects 
on the α7 AChR. The 3-arylidene-anabaseines are of special potential therapeutic interest because they 
have been shown to possess neuroprotective as well as cognition enhancing properties. Here we shall 
only consider 3-(2,4-dimethoxybenzylidene)-anabaseine (DMXBA), whose pharmaceutical code name 
GTS-21 refers to its origination as the 21st compound generated in a joint project by Gainesville 
(University of Florida) and Tokushima (Taiho Pharmaceuticals) Scientists. DMXBA was the first 
nicotinic agonist reported to selectively stimulate α7 AChRs; it was also the first α7 agonist to enter 
clinical tests for possible treatment of cognition problems such as occur in schizophrenia, 
Parkinsonism and Alzheimer’s disease (AD).  
DMXBA is prepared by reaction of 2,4-dimethoxybenzaldehyde with anabaseine in acidic alcohol 
at approximately 70oC, in a manner similar to the preparation of 3-(4-dimethylaminobenzylidene)-
anabaseine [39,40]. The resulting product can be precipitated and recrystallized using less polar 
solvents. Whereas the two rings of anabaseine have been shown to be electronically conjugated and 
thus nearly coplanar, all three rings of DMXBA are predicted to lie in different planes. Unlike 
anabaseine, 3-arylidene-anabaseines do not readily hydrolyze to open-chain forms at physiological 
pHs like anabaseine. In principle, these compounds can adopt two possible conformations with respect 
to the vinyl portion of the arylidene ring, namely E- or Z. By NMR we have shown that only the E 
form occurs in aqueous solution when the synthetic DMXBA dihydrochloride is dissolved in water 
[97]. Only after intense or maintained light exposure does the E to Z conversion become significant 
(Kem et al., unpublished data). Thus, the synthetic compound solid and stock solutions of the 
compound must be stored in containers that exclude light and stock. While photosensitivity of 
DMXBA was observed in the laboratory, when plasma samples from animal and human tests were 
prepared in an unlighted fume hood and subsequently determined by HPLC with a photodiode array 
detector, no Z-isomeric product was observed [71]. 
DMXBA is a lipophilic compound which readily passes across biological membranes including the 
gastrointestinal wall and the blood-brain barrier and reaches peak concentrations in the blood and brain 
within a very short time [14,48,51,59]. It is O-demethylated primarily at the p-position of the 
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benzylidene ring, but demethylation at the o-methoxy group also occurs to a much lesser extent. While 
the resulting hydroxy metabolites are actually more efficacious at the α7 receptor in vitro, their peak 
brain concentrations are much less than for DMXBA [51]. They are efficiently glucuronidated and 
excreted. Other anabaseine compounds in development are much less readily metabolized and possess 
better bioavailability. 
Based on the crystal structure of acetylcholine-binding protein (AChBP) [19], monomer, 
homodimer, and homopentamer models of the α7 AChR were derived [23]. Since the agonist binding 
sites are located at the subunit interface (reviewed in [3,4]), a detailed analysis about the interface, as 
well as its interaction with the Hepes molecule that has been observed in the AChBP crystal, was 
performed. Furthermore, a ligand-binding pocket was defined providing useful information for 
conducting various mutagenesis studies to get clues for drug design. Although computer-predicted 
protein structures are still not as accurate as X-ray structures, the three modeled structures can at least 
serve as a basis for designing new ligands [22].  
 
 
Figure 4. Close view of the α7 AChR binding pocket for 2OH-MBA (modified from [90]). 
The molecule is in the protonated form. Green and blue areas represent the hydrophobic and 
the hydrophilic surfaces, respectively, found in the binding pocket. The ligand is colored 
according to the atomic types: red (oxygen), gray (carbon), blue (nitrogen), and light-grey 
(hydrogen). 
 
Theoretical and molecular modeling studies were done to better understand the details of how 
DMXBA and its two primary O-demethylated metabolites (2OH- and 4OH-MBA) might bind to α7 
AChRs [90]. Figure 4 depicts a model of the binding pocket of 2OH-MBA at the extracellular domain 
of the α7 AChR. There was rather good accordance of the calculated preferred energies with the 
observed binding affinities [51]. Van der Waals repulsions made the dominated contribution to the 
predicted binding energy for the receptor. However, hydrophobic contacts were also observed. 
DMXBA and its metabolites seemed larger than the optimal size for fitting into the agonist binding 
site. Thus, one possible approach to improving the effectiveness of benzylidene-anabaseine binding 
might be to reduce the molecular volume while retaining the active groups. We are optimistic that 
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molecular modeling, in combination with experimental studies on model proteins such as AChBP [83], 
may provide a useful basis for rational design of nicotinic drug candidates for treating 
neurodegenerative and possibly other diseases.  
While DMXBA selectively stimulates α7 AChRs, at significantly higher concentrations it also is an 
antagonist of α4β2 AChRs and related type 3 5-HT receptors [51,58,66,94]. At even higher 
concentrations DMXBA also is a weak antagonist at other AChRs. In at least some AChR subtypes, 
DMXBA and its metabolites may actually exert a noncompetitive inhibition of channel activation 
(Table 1). For instance, it has been found that DMXBA at micromolar concentrations [inhibition 
constant (Ki) = 13 ± 1 µM] displaces the binding of [3H]thienylcyclohexylpiperidine ([3H]TCP) within 
the channel of the neuromuscular-type AChR [7,9]. While the 4-hydroxy metabolite also displayed this 
inhibitory binding, it occurred at a higher concentration (Ki = 48 ± 5 µM). Schild-type analyses of 
these experiments indicated that these competitions are mediated by a steric mechanism. Thus, 
considering that [3H]TCP is a structural and functional analog of the dissociative general anesthetic 
and potent noncompetitive antagonist phencyclidine (PCP), we suggest that the anabaseine analog 
binding site overlaps the PCP locus in the desensitized ion channel [7]. In this regard, photoaffinity 
labeling studies using [3H]ethidium diazide, which binds with high affinity to the PCP locus, helped to 
determine the structural components of this site in the desensitized state [73] (reviewed in [5,6,10]). 
The results indicated that residues Leu251 at position 9’ (e.g., the leucine ring) and Ser252 at position 
10’ from the α1-M2 transmembrane segment as well as other unknown amino acids located in the M1 
and M2 transmembrane segments from the δ subunit are structurally involved in the PCP binding site. 
In the resting state (in the presence of α-BTx), anabaseine analogs modulate either [3H]TCP, 
[3H]tetracaine, or [14C]amobarbital binding to the Torpedo AChR in an allosteric fashion. These results 
indicate that the anabaseine analog binding site overlaps neither the PCP, the tetracaine, nor the 
amobarbital binding domain in the resting ion channel. We suggested that the PCP binding site in the 
resting state is located more extracellularly than that in the desensitized state, probably close to the 
mouth of the external vestibule (probably after position 13’ and closer to position 20’) [8,11,13], 
whereas the barbiturate locus is located practically in the middle of the resting ion channel (between 
position 9’ and 13’) [12] (reviewed in [5,6,10]). In addition, the tetracaine binding domain bridges 
both the PCP and the amobarbital loci in the resting ion channel (probably between position 5’ and 20’) 
[31,67]. 
Interestingly, anabaseine analogs enhance [3H]TCP binding to the Torpedo AChR when the 
receptor is in the resting but activatable state (in the absence of α-BTx) [7,9]. We consider that this 
enhancement is due to an anabaseine analog-induced AChR desensitization process. This hypothesis 
was supported by the fact that anabaseine analogs also increase the binding of the agonist [3H]cytisine 
to the resting but activatable AChR. In this regard, AChR desensitization seems to be another 
mechanism by which anabaseine analogs produce the noncompetitive inhibition of AChRs, which in 
turn, might account for the partial agonistic effect of these compounds in α7 AChRs [26]. 
Considering this new experimental evidence it is plausible that the maximal channel activation 
observed in conventional voltage-clamp electrophysiological recordings might be influenced by the 
propensity of anabaseine analogs for causing channel block and/or desensitization as well as the 
probability of the bound agonist to trigger the conformational changes associated with moving from a 
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resting (closed but activatable) to an activated (open) channel state, to finally a desensitized (closed) 
conformation. 
What makes DMXBA of considerable scientific as well as potential clinical interest is its selective 
stimulation of α7 AChRs. The physiological function of this receptor had been very difficult to 
investigate in the past due to its propensity to rapidly desensitize when high concentrations of agonist 
are applied. Initially this receptor was only recognized by its ability to bind α-BTx. Later, after cloning 
and expression in cultured cells, it was found to be physiologically active as a ligand-gated ion channel 
with unusually high permeability for calcium ions. α7 AChRs occur at presynaptic as well as on 
postsynaptic sites at densities that are sometimes as high as that of glutamate receptors [28]. By 
causing an influx of calcium ions even at normal membrane resting potentials, when most voltage-
gated calcium channels are closed, these AChRs are able to stimulate a variety of second messenger 
systems responsive to elevations in intracellular calcium [24], including nitric oxide synthesis [1]. 
That DMXBA enhances performance in cognitive tasks indicates that α7 AChRs play a significant 
role in learning and memory [51,75]. That DMXBA and other nicotinic agonists primarily exert their 
cognition-enhancing actions through AChR stimulation rather than desensitization follows from the 
finding that their pro-cognitive effects are inhibited by administering nicotinic antagonists like 
mecamylamine, α-BTx and methyllycaconitine [55]. DMXBA and nicotine both enhance long-term 
potentiation (LTP) in the hippocampus [37,64]. One hypothesis is that stimulation of α7 receptors by 
released ACh or choline (an endogenous weak agonist) enhances the action of synaptically liberated 
glutamate on nearby N-methyl-D-aspartate (NMDA)-type glutamate receptors, as the depolarization 
resulting from α7 channel opening would eliminate the resting block of NMDA receptors by 
intracellular magnesium ions [60]. This could be a postsynaptic mechanism for nicotinic stimulation of 
LTP. 
DMXBA, like nicotine, enhances auditory gating in mice [78] and in humans [71]. The DMXBA 
enhancement displays less acute tolerance (i.e., reduced response with successive applications) than 
does the nicotine effect. Since the auditory gating effects of both compounds in mice are prevented by 
prior administration of α-BTx, α7 receptors are the dominant AChRs mediating this action. 
Schizophrenics suffer from a relative inability to filter or gate repetitive sensory stimuli, particularly 
auditory and visual stimuli [29,62]. This gating defect probably contributes to the negative symptoms 
of the disease, which are not well treated by neuroleptic drugs which in general are dopamine receptor 
antagonists. A recent recommendation by an expert panel of psychiatrists recommended development 
of new therapies for treating the cognitive problems associated with this disease, since they are 
particularly problematic in preventing schizophrenics from holding jobs and functioning in society. 
The University of Colorado and University of Florida labs have recently collaborated on a phase 1 test 
of DMXBA in schizophrenics. The results of this study, both regarding safety and initial assessments 
of efficacy, encourage further tests [71]. It has also been shown that the deleterious effects of cocaine 
on auditory gating can be counteracted by DMXBA [79]. Thus, α7 nicotinic agonists may also be 
useful in treating psychoses resulting from use of these stimulants.  
 
 
Table 1. Comparison of the relative activities of anabaseine, nicotine and DMXBA on several 
vertebrate AChRs. 
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α7                                            Full Agonist                                  Weak Partial Agonist               Partial Agonist 
α4β2                                        Weak Partial Agonist Strong Partial Agonist             Competitive Antagonist 
  
Sympathetic 
 PC12 Cell                          Partial Agonist Full Agonist                             Noncompetitive Antagonist  
 α3β4 (oocyte)          Partial Agonist Full Agonist                             Noncompetitive Antagonist  
 
Muscle-type 
     α1β1εδ                               Full Agonist Full Agonist                             1Competitive Antagonist 
     α1β1γδ (Torpedo)              Full Agonist Full Agonist                             2Noncompetitive Antagonist 
__________________________________________________________________________________________________
_ 
1 Weak potency; 2 Moderate affinity (data from refs. [7,9]). 
Data summarized from refs. [26,49,72]. 
 
Two decades ago a drastic decrease in AChRs was first reported in Alzheimer's patients and some 
Parkinson’s patients [92]. This finding stimulated considerable academic and pharmaceutical interest 
in the development of nicotinic agonists that could selectively stimulate the remaining brain AChRs 
involved in cognitive and other critical mental functions. At that time it was already apparent that 
cholinesterase inhibitors and non-selective muscarinic agonists were relatively weak therapeutic agents 
for counteracting the neurodegeneration and dementia associated with AD. DMXBA is a relatively 
unique drug candidate which readily enters the brain and acts as an α7 AChR partial agonist. Its 
effects upon cognitive behavior have been investigated by many laboratories using a variety of 
mammalian species (reviewed in [44]). Nucleus basalis-lesioned rats or aging rats, mice and rabbits 
were often used to simulate a cholinergic deficit. Initially it was observed that the compound enhanced 
passive avoidance performance in rats [65] and active avoidance in mice [2] and acquisition of 
conditioned eye-blink reflex in aging rabbits [93]. Memory of more intricate learning tasks such as 
water and radial maze performance by rats [17] and delayed matching by monkeys [20,21] was also 
enhanced, suggesting that the compound may be able to enhance cognition in aging humans, 
particularly AD patients. The latter paper is noteworthy in providing compelling evidence that single 
doses of relatively short plasma half-life (hours) nicotinic agonists are capable of enhancing cognition 
for relatively long periods of time (days). Generally, cognition enhancement is more readily 
demonstrated under conditions where cognitive function is deficient, as in chemically lesioned or 
aging animals. In the case of DMXBA performance on several cognitive tasks was even enhanced in a 
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phase 1 trial with healthy young male adults [53]. Thus, α7 nicotinic agonists may be useful in treating 
deficits in cognition, regardless of age. 
One advantage of targeting α7 receptors for therapeutic enhancement of cognition, instead of α4β2 
receptors, is that modulation of the former receptor does not seem to affect activities associated with 
nicotine dependence, namely hyperlocomotion, nicotine discrimination and nicotine self-
administration, whereas the latter receptor is thought to be a major mediator of the euphoric and 
anxiolytic effects of nicotine [34,86,89]. 
The actions of subcutaneously administered anabaseine and DMXBA upon the brain levels of ACh 
and several biogenic amines have been investigated using cerebral (frontoparietal location) 
microdialysis methods [82]. Anabaseine, like nicotine [80,81] and other α4β2 agonists, elevated ACh 
levels (Table 2). However, an equimolar (3.6 µmol/kg) dose of DMXBA did not affect ACh levels at 
this cortical site or within the hippocampus [84]. Both anabaseine and DMXBA elevated dopamine 
and norepinephrine levels, but did not significantly affect serotonin levels. However, when 
mecamylamine, a noncompetitive AChR antagonist, was administered thirty minutes before 
administration of either compound, significant increases in ACh and 5-HT levels were observed. 
Explanations for these extraordinary mecamylamine effects are not yet at hand; one possible 
interpretation would be that at the mecamylamine dose administered, the more sensitive α4β2 
receptors expressed on inhibitory (GABAergic) neurons innervating the basalis (cholinergic) and raphe 
(serotonergic) nuclei were preferentially inhibited, leaving the excitatory effects of anabaseine and 
DMXBA on the most resistant AChRs (α7) to be expressed without opposition from these inhibitory 
effects. Further investigation of the effects of α7 agonists upon brain neurotransmitter levels and their 
sensitivity to block by AChR antagonists is clearly warranted. 
 
Table 2. Comparison of the relative effects of equimolar (3.6 µmol/kg) subcutaneous doses of 
anabaseine, nicotine and DMXBA on various neurotransmitter levels in the rat prefrontal cortex, as 
measured by microdialysis methods. 
 ______________________________________________________________________ 
                                   Peak Effect (% Increase)  
Receptor Type 1Nicotine                                2Anabaseine                               2DMXBA 
____________________________________________________________________________________ 
 
Acetylcholine  106 50 NE3 
   
Dopamine  NE3 85 96  
  
Norepinephrine   86 62 83 
 
Serotonin  NE3                                            NE3 NE3 
____________________________________________________________________________________ 
1 Data taken from ref. [80]. 2 Data taken from ref. [82]. 3 No statistically significant effect. 
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Several laboratories have recently reported that β-amyloid (Aβ) binds to α7 receptors at very low 
concentrations. The peptide inhibits α-BTx binding to its ACh-binding site and has been reported to 
activate [27] or inhibit this AChR [27,33,87]. It was hypothesized that α7 receptors are a target of Aβ 
action on brain neurons. Electrophysiological analysis indicated a noncompetitive block of ACh 
activation of this receptor. The initially reported selective inhibition of α7 receptors was followed by 
reports from other laboratories that non-α7 AChRs are also affected by similarly low concentrations of 
the peptide [30,57]. If the α7 AChR were a major target for Aβ in generating AD, then one would 
predict that neurons bearing high concentrations of this receptor would be particularly susceptible and 
this would lead to a decrease in brain α7 receptors as the disease progresses. However, the loss of α7 
receptors in AD brains is much smaller than the loss of α4β2 AchRs [63]. α7 Receptor levels in 
transgenic mice overexpressing Aβ may be reduced [70] although this may occur very early in life [85]. 
α7 AChR concentrations in cultured neurons were not affected by Aβ exposure [25]. Further 
investigations of the interaction of Aβ with AChRs are needed to determine whether α7 and/or other 
AChRs are directly involved in mediating neuronal destruction in AD. 
Besides affecting cognitive functions, DMXBA and other nicotinic agonists also display 
neuroprotective properties such as inhibiton of the excitotoxic effects of Aβ [76] and high 
concentrations of ethanol [25,61,76]. In a stroke model, pre-administration of DMXBA was also able 
to reduce neuronal damage [68,69]. At very high concentrations (>10 µM), approximately 50 times 
higher than would occur under clinical conditions (200 nM), rapid addition of this compound to 
cultured neurons DMXBA was also excitotoxic [56]. If the compound was allowed to reach the cells 
gradually these high concentrations were not toxic. The neuroprotective effects of DMXBA were 
inhibited by reducing extracellular and intracellular calcium levels, and thus seem to be a consequence 
of calcium influx into the neuron [74]. 
Future Directions of Research 
These are interesting times for the investigation of AChRs and their roles in health and disease. 
Besides the brain AChR targets discussed above, several peripherally expressed AChRs may also be 
useful therapeutic targets for treating other disease states. Examples which readily come to mind are 
acute inflammation [88] and controlling the growth (angiogenesis) of new blood vessels [36,38]. In 
these two examples considerable evidence already exists pointing to a major role of α7-type receptor 
involvement. In this article we hope to have convinced the reader that naturally occurring toxins acting 
on AChRs, besides being useful probes for particular nicotinic receptors, can also serve as molecular 
models for the design of nicotinic agonists and antagonists of possible therapeutic utility.  
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